82 results about "Subcutaneous implant" patented technology

An embodiment relates to an active implantable medical device (AIMD) comprising: a permeability module to allow ingress of a fluid into an osmotic agent chamber of the AIMD, a compressible piston, a drug chamber comprising a drug or being provided to receive a drug and a valve module to allow flow of the drug from the drug chamber to outside the AIMD through one or more drug outlets present in the AIMD, wherein the AIMD has dimensions that allow the AIMD to be implanted, subcutaneously, in a human body.

Methods and implantable medical devices are provided that include a lead configured to be operably coupled to a pulse generator and subcutaneously implanted within a patient. The lead includes an electrode configured to receive electrical power from the pulse generator and to deliver high-voltage shocks for defibrillation therapy. The electrode has an oblong cross-sectional shape with a major dimension that is at least 10 French (F).

Long-lasting biodegradable subcutaneous implant with prolonged release of pharmacologically active substance pre-concentrated in polymer for the treatment of epilepsy using from 10 to 1000 mg essential oil extracted from Cannabis sativa and / or Cannabis indica (full or broad spectrum), 10 to 500 mg natural or synthetic tetrahydrocannabidiol (THC) isolate, 10 to 500 mg natural or synthetic cannabidiol (CBD) isolate, proportional combination of broad spectrum essential oil and CBD isolate, proportional combination of full spectrum essential oil and natural or synthetic CBD isolate, or proportional combination of natural or synthetic THC isolate and CBD isolate in polymeric matrix for adjuvant treatment of epilepsy, chronic pain and anxiety.

The utility model relates to the technical field of medical instruments, and discloses a wire puncture structure and a medical tool. Wherein the wire puncture structure comprises a puncture cannula, a connecting sleeve and a wire, and the puncture cannula is provided with a guide hole; the connecting sleeve can extend into the guide hole and is detachably connected to the puncture cannula, and a fixing hole is formed in the connecting sleeve; the wire is connected to the fixing hole. When the puncture sleeve is used, a channel is formed under the skin, the puncture sleeve is placed in the subcutaneous channel, at the moment, the middle of the puncture sleeve is located in the channel, the two ends of the puncture sleeve are located outside the channel, then the connecting sleeve extends into the guide hole from the first end of the puncture sleeve and is connected to the puncture sleeve, the second end of the puncture sleeve is dragged, and the puncture sleeve is inserted into the guide hole. The puncture cannula carries the connecting sleeve and the lead to be pulled out from a subcutaneous channel together, and subcutaneous implantation of the lead is achieved. According to the wire puncture structure, on one hand, the risk that the wire is loosened from the puncture sleeve on the half way when directly penetrating through the puncture sleeve is reduced; and on the other hand, the subcutaneous puncture efficiency of the wire is improved.

An apparatus is provided for subcutaneous implantation in a patient using a tunneling instrument. The implantation apparatus comprises a vascular graft and a connector adapted to couple a distal end of the tunneling instrument and a proximal end of the graft. The connector comprises a tip, a first end of the tip configured to be received within the proximal end of the graft, a clip for securing the graft to the tip, and a coupler for a rotatable connection of the tip to the tunneling instrument such that the tip is rotatable about its longitudinal axis relative to the coupler to facilitate attachment of the graft to the tunneling instrument. The implantation apparatus may further comprise a removable sheath configured to substantially cover the length of the graft.

A system may include one implantable pulse generator and at least one implantable lead. The pulse generator may include a processor, a driving system for driving electrodes, a communication circuit, and a housing configured to be subcutaneously implanted. The lead may be configured to extend from the pulse generator to at least one neural target on a left side of a head and a neural target on a right side of the head. The lead may include at least two electrode sets, each including at least two electrodes. The lead be configured to be used to subcutaneously place the at least two electrode sets near the at least two neural targets, respectively, and electrically connect the pulse generator to each of the at least two electrodes sets to enable the driving system to drive the at least two electrode sets to stimulate the at least two neural targets.

Systems and methods involving implants positioned within implant pockets through minimally invasive entrance incisions, along with related neurostimulatory implants. In some implementations, implants may be folded, rolled, or otherwise compressed to fit within subcutaneous implant pockets, after which they may be decompressed to fit within an implant pocket having one or more dimensions substantially larger than the entrance incision. Such implants may be used for a variety of purposes, including generating electrical energy for various other implants, including neurostimulatory implants located throughout the body.

In some examples, determining a heart failure status includes using an implantable medical device configured for subcutaneous implantation and comprising a plurality of electrodes and an optical sensor. Processing circuitry of a system comprising the device may determine, for a patient, a current tissue oxygen saturation value based on a signal received from the at least one optical sensor, a current tissue impedance value based on a subcutaneous tissue impedance signal received from the electrodes, and a current pulse transit time value based on a cardiac electrogram signal received from the electrodes and at least one of the signal received from the optical sensor and the subcutaneous tissue impedance signal. The processing circuitry may further compare the current tissue oxygen saturation value, current tissue impedance value, and current pulse transit time value to corresponding baseline values, and determine the heart failure status of the patient based on the comparison.

A hair implant suitable for subcutaneous implantation comprises (a) an anchor comprising: (i) an anchor body and (ii) at least one collagen receiving structure comprising at least one a tunnel disposed through the anchor body. The hair implant further comprises: (b) at least one hair element projecting from a distal end of the anchor body, wherein the hair implant is unitary in structure. The at least one collagen receiving structure is configured to support collagen ligature growth after subcutaneous implantation of the hair implant so as to anchor the anchor to a hair implant recipient.

Devices, systems and techniques are provided to facilitate chronic monitoring of biological signals. An implant device can include a set of branch portions. Each branch portion can include multiple electrodes disposed on a bottom surface and can have vias that connect the electrode to a trace on the top of the branch portion. Each branch portion can include a hole through which a connector (e.g., suture) can be pulled. The connector can also be threaded through a hole in a curved arm of an implantation tool, To implant the implant device, the implantation tool can be inserted through an incision, moved to a target location and stabilized. An end of the connector can then be pulled, which can cause the implant device to move to the target location. The implant device can then be stabilized and the implantation tool explanted.

The present application relates to the biomedical technology field, especially to a kind of decellularized pig pericardium and POSS-PEG-CHO cross-linked biological nanocomposite material and its preparation method and application.The present application is based on Schiff base reaction, and the star-shaped eight-arm eight-functionalized POSS-based benzaldehyde end-capped polyethylene glycol is used to cross-link the decellularized pig pericardium, and the POSS-PEG-PP biological nanocomposite material is successfully prepared.Compared with GLUT-PP, the POSS-PEG-PP provided by the present application presents more compact fiber arrangement, and the mechanical property is also better.In vitro experiment shows that POSS-PEG-PP has excellent cell compatibility, endothelialization capacity and blood compatibility.In vivo evaluation further confirms that the material has significant anti-inflammatory and anti-calcification properties.Through RNA sequencing analysis of subcutaneous implant, it is found that the changes of AMPK and IL-17 signal pathways play an important role in the process of POSS-PEG-PP regulating inflammation and immune response.Therefore, POSS-PEG-PP shows good application prospect in the field of biological heart valve, and is expected to become a very potential alternative material.

Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and / or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula / catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and / or occlusion over a period of time.

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

The invention discloses application of mesenchymal stem cell spheres in preparation of medicines for treating Alzheimer's disease, and relates to the technical field of biological medicines. According to the application of the mesenchymal stem cell sphere in preparation of the medicine for treating the Alzheimer's disease, the mesenchymal stem cell sphere has an excellent immune regulation effect, and after being prepared through the method, the mesenchymal stem cell sphere is implanted into a receptor subcutaneously, cognitive impairment of the receptor can be remarkably improved, memory defects of the receptor can be repaired, activation of microglial cells can be reduced, and the immune regulation effect of the mesenchymal stem cell sphere is improved. The compound can inhibit brain inflammation, and has certain application value in treatment of Alzheimer's disease.

The utility model relates to the technical field of subcutaneous implants in medical cosmetic plastic surgery, in particular to a prosthesis. The utility model discloses a prosthesis, the prosthesis comprises at least one prosthesis main body, the prosthesis main body is made of at least one layer of sheet-shaped bulky material distributed with micropore structures for tissue cell growth, the prosthesis main body is provided with a first component and a second component which are integrally processed, and the first component and the second component are arranged on the first component and the second component. The first component and the second component are respectively provided with an outer end side of a square head structure, and an included angle between the central axis of the square head structure of the first component and the central axis of the square head structure of the second component is an obtuse angle. The prosthesis is high in shape universality, a doctor can conveniently design deviation of the supporting legs through the square head design, meanwhile, the abundant micropore structures can induce tissue cells to grow in, and fusion of the tissue cells and the prosthesis body is achieved.

Systems and methods for improved cranio-maxillo-facial distraction are provided. The disclosed subject matter can include a distraction device adapted for subcutaneous implantation in a patient, and a handheld device operationally coupled to the distraction device. The distraction device can include a distraction element, adapted to attach to opposing bony fragments of a bone and perform distraction osteogenesis on the bone, and a rotatable magnetic element, coupled to the distraction element such that rotation of the magnetic element controls the distraction element. The handheld device can include a magnetic element, operationally coupled to and magnetically aligned with the magnetic element of the distraction device, such that rotation of the magnetic element of the handheld device causes corresponding rotation of the magnetic element of the distraction device. The disclosed subject matter also provides techniques for implanting a distraction device to opposing bony fragments of a bone and using such a device.

The application relates to the technical field of GnRH pumps, in particular to a GnRH pump based on real-time hormone level dynamic adjustment of infusion amount and a use method thereof, the GnRH pump comprises a pump body, a real-time hormone monitoring module, a control module, an infusion execution module, a medicine storage module, a communication module and a power module, the real-time hormone monitoring module collects hormone signals in real time through a subcutaneous implantable LH / FSH sensor, an artificial intelligence algorithm is built in the control module, real-time data is compared with a standard range, infusion adjustment instructions are dynamically generated, and the infusion execution module accurately infuses GnRH drugs according to the instructions, the use method comprises device installation and parameter presetting, real-time hormone monitoring, dynamic adjustment analysis, accurate infusion execution, data transmission and remote monitoring.The application solves the defects that the existing GnRH pump has no real-time feedback and cannot be automatically adjusted, realizes monitoring-feedback-regulation closed-loop control, improves treatment accuracy and individualized adaptability, and is suitable for the treatment of diseases such as hypogonadotropic hypogonadism.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

Title of the invention: Subcutaneous implant and method for mounting such a subcutaneous implant. The present invention relates to a subcutaneous implant (2) comprising a housing (4) including at least a first zone (6) in which measuring and / or communication equipment is housed, a second zone (8) in which at least one printed circuit board is housed, and a third zone (10) in which an electrical energy storage means is housed, the printed circuit board comprising a plurality of electronic components, including at least one accelerometer, the printed circuit board being housed in a support configured to position the printed circuit board at least with respect to the first zone (6) and / or with respect to the third zone (10) and to contribute to the electrical isolation of at least some of the electronic components from the housing (4). (Figure 1)

A subcutaneously implantable access device for accessing a vascular system of a human or animal body. The implantable access device includes a port body, a needle entrance with at least one inlet opening for receiving a needle and an outlet opening, and an at least partially flexible catheter for accessing the vascular system of the human or animal body. The at least partially flexible catheter is connected to the outlet opening of the needle entrance, and the needle entrance is connected to the port body and movable relative to the port body between a first, unactuated operating condition that prevents fluid flow through the at least partially flexible catheter and a second, actuated operating condition that allows the fluid flow through the at least partially flexible catheter.

A subcutaneously implantable device a first housing, a clip attached to the first housing that is configured to anchor the device to a muscle, a bone, and / or a first tissue, and circuitry in the first housing that is configured to provide monitoring, therapeutic, and / or diagnostic capabilities with respect to an organ, a nerve, the first tissue, and / or a second tissue. The circuitry includes sensing circuitry and / or therapy circuitry, a first power source, and a transceiver. The device further includes an antenna attachment extending away from the first housing, wherein the antenna attachment is in electrical communication with the first power source and the transceiver, and wherein at least a portion of the antenna attachment is configured to be subcutaneously positioned in a patient.

The present invention relates to a subcutaneous implant for hormone replacement therapy, comprising a shell and a core. The shell wraps around the outside of the core and is columnar as a whole. The shell comprises estrogen and a biodegradable polymer, and the core comprises an estrogen receptor inhibitor and a biodegradable polymer. When implanted into the body, the estrogen in the shell starts to continuously and stably release a fixed amount of drug daily. As the drug in the shell dissolves and diffuses and the material degrades, the active drug in the core gradually and slowly releases after a certain period of drug administration, realizing sequential combined administration of two active substances in a single implant.

The present invention relates to a subcutaneous implant for hormone replacement therapy, which comprises a shell and a core. The shell wraps around the outside of the core and has an overall columnar structure. The shell comprises an androgen and a biodegradable polymer, and the core comprises an enzyme inhibitor and a biodegradable polymer. The enzyme inhibitor comprises a 5-α reductase inhibitor and an aromatase inhibitor. When implanted into the body, the androgen in the shell continuously releases a fixed amount of drug stably every day. As the drug in the shell dissolves and diffuses and the material degrades, the active drug in the core gradually releases slowly after a certain period of drug administration, realizing sequential combined administration of two active substances in a single implant.

A control assembly for implantation in a patient comprises a first unit adapted for subcutaneous implantation at a first side of a body tissue of said patient, a second unit adapted for implantation in a body cavity of said patient at a second side of said body tissue, wherein at least one of the first and the second unit is adapted to control an implanted powered medical device, and an interconnecting device adapted for mechanical interconnection of the first and second units to keep the assembly in place by the body tissue, the interconnecting device having a cross-sectional area which is smaller than the cross-sectional area of the first unit and the second unit in a plane parallel to the extension of the body tissue.

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

An implantable medical device for use as an artificial urinary bladder can include a collection container configured to be placed in a patient's abdominal cavity and a pump configured to be subcutaneously placed outside the abdominal cavity to allow the patient to perceive the need for urination and controls timing of the urination. Flexible tubing can connect the patient's ureters to the collection container through anti-reflux valves preventing urine from flowing back to kidneys, connect the collection container to the pump through a unidirectional connection valve, and connect the pump to the patient's urethra through a unidirectional urethral valve to allow for urination through the patient's natural urethra.

A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit. Preferably, the compliant member is adapted to be implanted in a pulmonary artery and the reservoir is adapted to be implanted subcutaneously. The external components may include a clinical controller component, monitoring software configured to run a clinician's computer, a patient monitoring device, and a mobile application configured to run on a patient's mobile device.

A system may include one implantable pulse generator and at least one implantable lead. The pulse generator may include a processor, a driving system for driving electrodes, a communication circuit, and a housing configured to be subcutaneously implanted. The lead may be configured to extend from the pulse generator to at least one neural target on a left side of a head and a neural target on a right side of the head. The lead may include at least two electrode sets, each including at least two electrodes. The lead be configured to be used to subcutaneously place the at least two electrode sets near the at least two neural targets, respectively, and electrically connect the pulse generator to each of the at least two electrodes sets to enable the driving system to drive the at least two electrode sets to stimulate the at least two neural targets.

The present disclosure provides methods and a device for thyroxine delivery. This device is designed for subcutaneous implantation to ensure continuous delivery of thyroxine. It features a reservoir regulated by an embedded microprocessor with advanced signal software. The software triggers a precision pump to release a specific dose of thyroxine at regular intervals. This system enhances patient compliance and maintains optimal metabolic control.

A hair implant suitable for subcutaneous implantation is provided having an anchor comprising an anchor body, and at least one collagen receiving structure selected from the group consisting of at least one tunnel disposed through the anchor body or an external surface feature of the anchor body. The anchor further comprises at least one hair strand projecting from a distal end of the anchor body and alternatively wherein the at least one hair strand includes a bend, wherein the at least one collagen receiving structure, or the external surface feature, is configured to support collagen ligature growth after subcutaneous implantation of the hair implant so as to anchor the hair implant in the recipient. The hair implant includes a two-part construction having a base module formed of the anchor body and at least one hair stem configured for coupling with a long hair strand. Another hair implant alternative includes a hair strand having a first end that is passed through the skin, underneath and the up through the skin at another location to result in the hair strand having two portions projecting from the skin surface.